Patents Assigned to UCB Biopharma SPRL
-
Publication number: 20220162311Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.Type: ApplicationFiled: December 9, 2021Publication date: May 26, 2022Applicant: UCB BIOPHARMA SPRLInventors: Paul Alan ATHERFOLD, Thomas Allen CESKA, Helene Margaret FINNEY, Lara KEVORKIAN, Kaushik SARKAR, Bryan John SMITH, Kerry Louise TYSON
-
Patent number: 11331438Abstract: Provided is a cap for an injector comprising a syringe with a needle cover. The cap comprises a first cap body part in the form of a sleeve having forward and rear openings; a second cap body part in the form of a plug arranged for receipt by said forward opening of said sleeve form first cap body part, wherein said plug form second body part defines a plug top and an inner plug body, and wherein said inner plug body defines a protruding pocket; and arranged for receipt within said protruding pocket of the inner plug body, a metal connector defining plural needle cover gripping elements arranged around a central hub, wherein each gripping element is provided with one or more barbs for gripping the needle cover. The first cap body part, second cap body part and connector are provided as separate parts.Type: GrantFiled: April 25, 2018Date of Patent: May 17, 2022Assignee: UCB BIOPHARMA SPRLInventors: Barry Alan Knight, Marko Frederik Plevnik, Norihiko Inoue, Jamie Buckley, Lisa Hornsey
-
Patent number: 11324896Abstract: Provided is a cap for an injector comprising a syringe with a needle cover. The cap comprises a cap body defining an inner and outer cap body; provided to the inner cap body, a grip for gripping the needle cover of said syringe; provided to the outer cap body, an opposing pair of recessed portions, wherein each recessed portion defines a recess base, and wherein each recessed portion is bounded by a peripheral lip; and provided to the recess base of each recessed portion, an over-coating. The cap body comprises a generally rigid material and each over-coating comprises a more flexible material. Each peripheral lip defines banks that extend beyond the over-coating of the recess base.Type: GrantFiled: April 25, 2018Date of Patent: May 10, 2022Assignee: UCB BIOPHARMA SPRLInventors: Barry Alan Knight, Marko Plevnik, Norihiko Inoue, Jamie Buckley, Lisa Hornsey
-
Patent number: 11220547Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.Type: GrantFiled: March 12, 2019Date of Patent: January 11, 2022Assignee: UCB Biopharma SPRLInventors: Paul Alan Atherfold, Thomas Allen Ceska, Helene Margaret Finney, Lara Kevorkian, Kaushik Sarkar, Bryan John Smith, Kerry Louise Tyson
-
Publication number: 20210371547Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.Type: ApplicationFiled: January 19, 2021Publication date: December 2, 2021Applicant: UCB BIOPHARMA SPRLInventors: Simon Peter TICKLE, Heather Margaret LADYMAN
-
Patent number: 11059820Abstract: Crystalline forms of seletalisib, designated as Form B and Form F and characterized herein, being selective inhibitors of PI3 kinase enzymes, in particular of the human PBK? isoform, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.Type: GrantFiled: May 24, 2018Date of Patent: July 13, 2021Assignee: UCB Biopharma SPRLInventors: Luc Lambert Jozef Jan Aerts, Georges Assaf, Nicolas Edmond Carly, Vincent Adolphe Carol Cool, Jean-Pierre Delatinne, Laurent Jacques Willy Delhaye, Jean Paul Kestemont, Sarah Le Meur
-
Patent number: 10889640Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.Type: GrantFiled: May 13, 2019Date of Patent: January 12, 2021Assignee: UCB BIOPHARMA SPRLInventors: David Edward Ormonde Knight, Terence Seward Baker, David James McMillan, Robert Anthony Griffin, Georges Mairet-Coello, Patrick Downey, Jean-Philippe Courade
-
Publication number: 20200377578Abstract: This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.Type: ApplicationFiled: July 2, 2020Publication date: December 3, 2020Applicant: UCB Biopharma SPRLInventors: David Paul Humphreys, Daniel John Lightwood, Kerry Louise Tyson, David Edward Ormonde Knight, Karine Jeannine Madeleine Hervé, Joanne Elizabeth Compson, Matthew Jon Timothy Page, Andrew Charles Payne, Nicola Louise Fisher, Brendon MacKenzie, Matthew Cox
-
Patent number: 10828366Abstract: The present invention provides method of increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises: a) a conversion step of treating the composition with a denaturant selected from urea and/or Guanidine hydrochloride; b) wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.Type: GrantFiled: April 22, 2016Date of Patent: November 10, 2020Assignee: UCB BIOPHARMA SPRLInventors: Sam Philip Heywood, Gavin Barry Wild, Razwan Hanif, Christopher John Le Page
-
Patent number: 10829565Abstract: The present invention provides method for increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises a) a thermal conversion step of holding the composition comprising the antibody molecule at a temperature in the range 30 to 60° C. for a period of at least 1 hour, wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.Type: GrantFiled: April 22, 2016Date of Patent: November 10, 2020Assignee: UCB BIOPHARMA SPRLInventors: Sam Philip Heywood, Gavin Barry Wild, Christopher John Le Page, Razwan Hanif
-
Publication number: 20200291013Abstract: The present invention relates to certain bis-heteroaryl compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.Type: ApplicationFiled: January 23, 2018Publication date: September 17, 2020Applicant: UCB Biopharma SPRLInventors: Adrian HALL, Malcolm MACCOSS
-
Patent number: 10774152Abstract: The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.Type: GrantFiled: July 16, 2015Date of Patent: September 15, 2020Assignee: UCB BIOPHARMA SPRLInventors: Helene Margaret Finney, Stephen Edward Rapecki, Michael John Wright, Kerry Louise Tyson
-
Publication number: 20200277366Abstract: The invention relates to multi-specific antibody molecules having specificity for TNF alpha, IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.Type: ApplicationFiled: December 14, 2016Publication date: September 3, 2020Applicant: UCB Biopharma SPRLInventors: Ralph ADAMS, Pallavi BHATTA, Emma DAVE, Sam Philip HEYWOOD, David Taul HUMPHERYS, Diane MARSHALL, Stevan Graham SHAW, Daniel John LIGHTWOOD
-
Patent number: 10759844Abstract: The present disclosure provides an antibody or antibody fragment comprising at least one Fab molecule, wherein the light chain variable region, VL and the heavy chain region, VH of the Fab molecule are linked by one or more disulfide bonds, and use of the same in treatment or prophylaxis.Type: GrantFiled: April 27, 2015Date of Patent: September 1, 2020Assignee: UCB BIOPHARMA SPRLInventor: David Paul Humphreys
-
Patent number: 10752676Abstract: This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.Type: GrantFiled: September 10, 2012Date of Patent: August 25, 2020Assignee: UCB Biopharma SPRLInventors: David Paul Humphreys, Daniel John Lightwood, Kerry Louise Tyson, David Edward Ormonde Knight, Karine Jeannine Madeleine Hervé, Joanne Elizabeth Compson, Matthew Jon Timothy Page, Andrew Charles Payne, Nicola Louise Fisher, Brendon Mackenzie, Matthew Cox
-
Patent number: 10730952Abstract: The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.Type: GrantFiled: July 16, 2015Date of Patent: August 4, 2020Assignee: UCB BIOPHARMA SPRLInventors: Helene Margaret Finney, Stephen Edward Rapecki, Michael John Wright, Kerry Louise Tyson
-
Publication number: 20200188607Abstract: Provided is a cap for an injector comprising a syringe with a needle cover. The cap comprises a first cap body part in the form of a sleeve having forward and rear openings; a second cap body part in the form of a plug arranged for receipt by said forward opening of said sleeve form first cap body part, wherein said plug form second body part defines a plug top and an inner plug body, and wherein said inner plug body defines a protruding pocket; and arranged for receipt within said protruding pocket of the inner plug body, a metal connector defining plural needle cover gripping elements arranged around a central hub, wherein each gripping element is provided with one or more barbs for gripping the needle cover. The first cap body part, second cap body part and connector are provided as separate parts.Type: ApplicationFiled: April 25, 2018Publication date: June 18, 2020Applicant: UCB Biopharma SPRLInventors: Barry Alan KNIGHT, Marko Frederik PLEVNIK, Norihiko INOUE, Jamie BUCKLEY, Lisa HORNSEY
-
Patent number: 10639423Abstract: Provided is a drive unit for an auto-injector having a drive unit housing arranged for docking receipt of a syringe or of a cassette unit comprising a syringe movable from a rest position, in which a needle tip of the syringe is within the drive unit housing to a use position, in which the needle tip protrudes from a needle delivery aperture; and a drive arrangement including one or more electrically powered sources of axial drive; a first drive transfer element for advancing the syringe to said use position; and a second drive transfer element for moving a plunger into the barrel of the syringe to eject liquid contents thereof. The drive unit housing is provided with a skin sensor arrangement having an array of plural skin sensor electrodes located about the needle delivery aperture.Type: GrantFiled: October 23, 2017Date of Patent: May 5, 2020Assignee: UCB BIOPHARMA SPRLInventors: Martin John McLoughlin, Michael James David Heald, Cameron Townley Charles, Dylan Sanders Garrett, Kevin Richard Lozeau
-
Patent number: 10639424Abstract: Provided is a drive unit for an auto-injector having a drive unit housing arranged for docking receipt of a syringe or of a cassette unit comprising a syringe movable from a rest position, in which a needle tip of the syringe is within the drive unit housing to a use position, in which the needle tip protrudes from a needle delivery aperture; and a drive arrangement including one or more electrically powered sources of axial drive; a first drive transfer element for advancing the syringe to said use position; and a second drive transfer element for moving a plunger into the barrel of the syringe to eject liquid contents thereof. The drive unit housing is provided with a skin sensor arrangement having an array of plural skin sensor electrodes located about the needle delivery aperture.Type: GrantFiled: December 5, 2017Date of Patent: May 5, 2020Assignee: UCB BIOPHARMA SPRLInventors: Martin John Mcloughlin, Michael James David Heald, Cameron Townley Charles, Dylan Sanders Garrett, Kevin Richard Lozeau
-
Patent number: 10626143Abstract: The present invention provides a novel method for manufacturing a protein, particularly where said protein is to be coupled with another molecule. The invention further provides a method for industrial scale protein manufacturing to obtain proteins, e.g., for therapeutic purposes.Type: GrantFiled: December 18, 2015Date of Patent: April 21, 2020Assignee: UCB BIOPHARMA SPRLInventors: Christopher Mark Illidge, Neil Alan Watson